| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.07. | Novo, Alvotech face continued FDA scrutiny at plants tied to recent FDA rejections | ||
| 17.07. | Fierce Pharma Asia-GSK, Merck ADCs' trial wins; AstraZeneca's $1.5B EGFR buy; Biotechs' new patent tricks | ||
| 17.07. | Foundation Medicine launches 'Quality First' initiative to stand out in cancer testing market | ||
| 16.07. | Huahai poaches quality chief from Hengrui amid FDA manufacturing citations | ||
| 16.07. | Vanda shifts Nereus marketing into high gear with Schumacher IndyCar sponsorship | ||
| 16.07. | Bipartisan Senate bill seeks to build vigilance around foreign companies making drugs in US | ||
| 16.07. | Merck scores at FDA as Lipfendra becomes world's first oral PCSK9 treatment | ||
| 16.07. | Otters, bears and Pharma Lions: inside Gilead's bronze-winning Cannes spot | ||
| 15.07. | Sanofi opens new chapters in Pfizer, Moderna mRNA patent litigation sagas | ||
| 15.07. | Novo gains head start on Lilly with European Commission approval of Wegovy pill | ||
| 15.07. | Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first | ||
| 15.07. | No patent protection for Stelara? No problem for J&J as Tremfya fills the void | ||
| 15.07. | Buzzy Veradermics shows its oral minoxidil can tackle female pattern hair loss, too | ||
| 15.07. | Kelun scores sac-TMT win in first-line NSCLC population missing from Merck's massive phase 3 program | ||
| 15.07. | Sanofi teams up with Special Olympics Unified Football World, raises respiratory health awareness | ||
| 14.07. | With FDA approval for its breast cancer blockbuster hopeful, Celcuity could 'belong in the hands' of a Big Pharma | ||
| 14.07. | Director's Note on What to Expect at the 2026 Partnerships with Sites Summit | ||
| 14.07. | Inside agency view: Havas SO on authenticity, connection and pushing back against the 'sea of sameness' | ||
| 14.07. | Huyabio scores with Opdivo combo in 'milestone' skin cancer trial | ||
| 14.07. | AstraZeneca pays up to $1.5B for EGFR lung cancer drug Zegfrovy from its spinoff Dizal | ||
| 14.07. | Real Chemistry builds body of AI healthcare commercialization tools with Anatomi launch | ||
| 13.07. | FDA's latest onshoring move homes in on streamlined facility registration, foreign plant scrutiny | ||
| 13.07. | Lupin recalls more than 2.5M prescription eye drop bottles, citing possible contamination | ||
| 13.07. | GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win | ||
| 13.07. | Germany pushes through healthcare reform package despite pharma's drug discount resistance |